Business
Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix® Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases
DIJON, France & STRASBOURG, France, January 08, 2026--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of
About this update from Oncodesign Precision Medicine S.a.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/126e131a76eeb86c3c11bcfbdc0bf127"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nKsvB_DoZ0n5tLIFxvYbbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/126e131a76eeb86c3c11bcfbdc0bf127","width":480,"height":320}},"lazy":false},{"type":"text","content":"DIJON, France & STRASBOURG, France, January 08, 2026--(BUSINESS WIRE)--Regulatory News:","length":91,"tagName":"p"},{"type":"text","content":"Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.","length":459,"tagName":"p"},{"type":"text","content":"Under this partnership, Ksilink will evaluate OPM's Nanocyclix® library of assets using its advanced high-throughput phenotypic screening platforms. The approach involves analyzing the effects of a molecule directly on patient-derived cells using a unique AI-assisted phenotyping method that can be applied to many therapeutic areas. This collaboration aims to identify new small molecule modulators that may address significant unmet medical needs in the field of neurodegenerative and neurodevelopmental disorders.","length":520,"tagName":"p"},{"type":"text","content":"Ksilink's high-content phenotyping technologies enable the capture of subtle cellular pathomorphologies relevant to the disease under study, directly from patient cells. Combined with OPM's Nanocyclix® technology, a proprietary platform of macrocyclic small molecules known for their high selectivity and potency in kinases, this partnership aims to accelerate the discovery of first-in-class therapeutic candidates.","length":424,"tagName":"p"},{"type":"text","content":""We are pleased to initiate this collaboration with Oncodesign Precision Medicine to explore the potential of Nanocyclix® molecules in our mod...